Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Background: To determine the clinical activity and safety of Chinese herbal medicine (CHM) combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in patients with advanced pulmonary adenocarcinoma (ADC) and the ability of CHM combined with EGFR-TKI to activate EGFR muta...

Full description

Bibliographic Details
Main Authors: Lijing Jiao, Jianfang Xu, Jianli Sun, Zhiwei Chen, Yabin Gong, Ling Bi, Yan Lu, Jialin Yao, Weirong Zhu, Aihua Hou, Gaohua Feng, Yingjie Jia, Weisheng Shen, Yongjian Li, Ziwen Zhang, Peiqi Chen, Ling Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Pharmacology
Subjects:
pulmonary adenocarcinoma
EGFR activating mutations
EGFR-TKI
Chinese herbal medicine
drug resistance
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00732/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00732/full

Similar Items